目的 探讨红花注射液联合注射用尿激酶治疗急性心肌梗死的临床疗效。方法 选取2019年8月—2020年11月在信阳市中心医院就诊的84例急性心肌梗死患者，按照随机数字表法将所有患者分为对照组和治疗组，每组各42例。对照组静脉滴注注射用尿激酶，10万UI加入250 mL生理盐水静脉滴注，在90 min滴完。治疗组在对照组基础上静脉滴注红花注射液，20 mL加入到250 mL葡萄糖注射液中充分稀释，1次/d。两组患者连续治疗14 d。观察两组的临床疗效，比较两组患者治疗前后心绞痛程度、心功能指标和血清炎性因子水平。结果 治疗后，治疗组的总有效率为95.24%，对照组的总有效率为80.95%，组间比较有显著性差异（P<0.05）。治疗后，两组的VAS评分明显降低（P<0.05），且治疗组VAS评分明显低于对照组（P<0.05）。治疗后，两组的左室射血分数（LVEF）、每搏输出量（SV）明显升高，左室收缩末容积（LVESV）明显降低（P<0.05）；治疗后，治疗组的LVEF、SV高于对照组，LVESV低于对照组，差异有统计学意义（P<0.05）。治疗后，两组的肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、脑钠肽（BNP）水平显著降低（P<0.05）；治疗组的TNF-α、IL-6、BNP水平低于对照组，差异有统计学意义（P<0.05）。结论 红花注射液联合注射用尿激酶可提高急性心肌梗死的疗效，有助于改善心功能，减轻心绞痛程度和炎症反应。

Objective To investigate the clinical efficacy of Honghua Injection combined with Urokinase for injection in treatment of acute myocardial infarction. Methods Patients (84 cases) with acute myocardial infarction in Xinyang Central Hospital from August 2019 to November 2020 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were iv administered with Urokinase for injection, 100 thousand UI added into normal saline 250 mL, dripped at 90 min. Patients in the treatment group were iv administered with Honghua Injection on the basis of the control group, 20 mL added into glucose injection 250 mL, once daily. Patients were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the degree of angina pectoris, the index of cardiac function, and the levels of serum inflammatory factors in two groups were compared. Results After treatment, the total effective rate of the treatment group was 95.24%, and that of the control group was 80.95%, with significant difference between the two groups (P<0.05). After treatment, the VAS score of two groups were significantly decreased (P<0.05), and the VAS score of the treatment group was significantly lower than that of the control group (P<0.05). After treatment, the LVEF and SV of two groups were significantly increased, but the LVESV was significantly decreased (P<0.05). After treatment, the LVEF and SV of the treatment group were higher than those of the control group, but the LVESV was lower than that of the control group, the difference was statistically significant (P<0.05). After treatment, the levels of TNF-α, IL-6, and BNP in two groups were significantly decreased (P<0.05). After treatment, the levels of TNF-α, IL-6, and BNP in the treatment group were lower than those in the control group (P<0.05). Conclusion Honghua Injection combined with Urokinase for injection can improve the efficacy of acute myocardial infarction, help to improve cardiac function, reduce the degree of angina pectoris and inflammatory reaction.

R972

河南省高等学校重点科研项目（19A320028）